Moderna Edges Closer To Becoming A Mid-Stage Drug Development Company

 
• By Jessica Merrill

The mRNA specialist outlined ambitious plans to bring a vaccine for cytomegalovirus to market during an R&D day after releasing positive Phase I data.

micro RNA (let7; pink) bound to mRNA (lin-41; cyan). miRNAs are small non-coding RNA molecules important for gene regulation and implicated in cancer, obesity and heart disease. - Illustration
Moderna is moving forward with mRNA clinical canidates • Source: Shutterstock

Moderna Inc. hopes to move a wholly owned messenger RNA (mRNA) vaccine for cytomegalovirus (CMV) into Phase III development quickly after releasing positive interim Phase I results. The company announced the clinical data on 12 September and held an R&D day in New York City highlighting the development strategy for the vaccine, mRNA-1647, and other pipeline ambitions.

The product will be one of the company's first to move into mid-stage development, so it is getting a lot...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

 
• By Edwin Elmhirst

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

Executives On The Move: Fable Therapeutics Gains CMO From AstraZeneca

Recent moves in the industry include changes at the top at 32 Biosciences, plus new CEOs at Idorsia, Courage Therapeutics and Oncolytics Biotech.